Bluebird Bio Inc. (NASDAQ:BLUE) shares were down 0.4% during mid-day trading on Friday . The stock traded as low as $47.50 and last traded at $48.62, with a volume of 533,584 shares. The stock had previously closed at $48.83.

Several research analysts recently issued reports on BLUE shares. Maxim Group reissued a “buy” rating and issued a $105.00 price objective on shares of Bluebird Bio in a research note on Wednesday, April 20th. BTIG Research reissued a “buy” rating and issued a $72.00 price objective on shares of Bluebird Bio in a research note on Wednesday, April 20th. Goldman Sachs Group Inc. reissued a “buy” rating and issued a $149.00 price objective on shares of Bluebird Bio in a research note on Monday, April 11th. Piper Jaffray Cos. reissued a “buy” rating and issued a $117.00 price objective on shares of Bluebird Bio in a research note on Saturday, March 19th. Finally, Vetr cut Bluebird Bio from a “strong-buy” rating to a “buy” rating and set a $55.90 price objective on the stock. in a research note on Wednesday, April 6th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $96.09.

The company’s market capitalization is $1.80 billion. The stock’s 50-day moving average price is $43.04 and its 200 day moving average price is $46.70.

Bluebird Bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, May 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by $0.29. The company earned $1.50 million during the quarter, compared to analyst estimates of $4.50 million. The company’s revenue was down 76.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.76) earnings per share. Equities analysts anticipate that Bluebird Bio Inc. will post ($5.90) EPS for the current year.

In other Bluebird Bio news, insider Philip D. Gregory sold 2,931 shares of the company’s stock in a transaction on Thursday, June 16th. The stock was sold at an average price of $39.52, for a total value of $115,833.12. Following the completion of the transaction, the insider now owns 30,069 shares in the company, valued at approximately $1,188,326.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Davidson sold 1,000 shares of the company’s stock in a transaction on Friday, April 15th. The shares were sold at an average price of $49.63, for a total value of $49,630.00. Following the completion of the transaction, the insider now owns 10,600 shares of the company’s stock, valued at approximately $526,078. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have made changes to their positions in the company. State Board of Administration of Florida Retirement System increased its position in shares of Bluebird Bio by 6.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 37,859 shares of the company’s stock worth $2,431,000 after buying an additional 2,385 shares during the period. Nationwide Fund Advisors increased its position in shares of Bluebird Bio by 40.8% in the fourth quarter. Nationwide Fund Advisors now owns 40,800 shares of the company’s stock worth $2,620,000 after buying an additional 11,830 shares during the period. Rhumbline Advisers increased its position in shares of Bluebird Bio by 6.0% in the fourth quarter. Rhumbline Advisers now owns 35,855 shares of the company’s stock worth $2,303,000 after buying an additional 2,023 shares during the period. California Public Employees Retirement System increased its position in shares of Bluebird Bio by 157.2% in the fourth quarter. California Public Employees Retirement System now owns 94,400 shares of the company’s stock worth $6,062,000 after buying an additional 57,700 shares during the period. Finally, Columbus Circle Investors increased its position in shares of Bluebird Bio by 170.2% in the fourth quarter. Columbus Circle Investors now owns 315,957 shares of the company’s stock worth $20,291,000 after buying an additional 199,014 shares during the period.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.